ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis

Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the rol...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2016
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/26038
Acceso en línea:
https://doi.org/10.1016/j.bcp.2016.02.005
https://repository.urosario.edu.co/handle/10336/26038
Palabra clave:
T lymphocytes
CD28
ICOS
Phosphatidyl inositol-3 kinase
PI3K inhibitors
Rheumatoid arthritis
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_8eefc64f80d51baceda40fdc7838118c
oai_identifier_str oai:repository.urosario.edu.co:10336/26038
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 175531a3-a87d-4f50-81d7-b93272ef39d909bbecfb-59a5-4bea-b599-68e3a93b712ef68a9ea5-0fc2-4167-b307-b664e125c9c93836193360053eb2bb9-f0d0-4279-85f5-c7d98ba17d258839912c-dd88-4484-a998-1ff966dd3ff1bf02ce56-51b6-498d-a1e3-3ea0dba51fcb6bacd80e-8f91-4aef-b462-1b65301be0d0dc1a385a-bd83-4dae-aefc-375aa290b0c332a524b7-78e3-4fcd-8b3b-352d71ff22680d1e6f49-f17a-4fb7-82f8-659f07b1ab1eb9d8359d-2484-4cf2-8d1f-cf11725766cb2020-08-06T16:20:30Z2020-08-06T16:20:30Z2016-04-15Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the role of p110? is less well understood. Here, a novel dual p110?/? inhibitor (ETP-46321) and highly specific p110? (A66) or p110? (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4+ T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110? inhibitor than by the p110? inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-?), T-bet expression and NFAT activation. In activated CD4+ T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-? better than A66. The p110?/? inhibitor ETP-46321, or p110? plus p110? inhibitors also inhibited IL-21 secretion by differentiated CD4+ T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-?, or clinical symptoms. Hence, p110? as well as p110? Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.application/pdfhttps://doi.org/10.1016/j.bcp.2016.02.005ISSN: 0006-2952EISSN: 1873-2968https://repository.urosario.edu.co/handle/10336/26038engElsevier6956Biochemical PharmacologyVol. 196Biochemical Pharmacology, ISSN: 0006-2952;EISSN: 1873-2968, Vol.196 (2016); pp.56-69https://www.sciencedirect.com/science/article/abs/pii/S0006295216000848?via%3DihubRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecBiochemical Pharmacologyinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURT lymphocytesCD28ICOSPhosphatidyl inositol-3 kinasePI3K inhibitorsRheumatoid arthritisETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritisETP-46321, un inhibidor dual de la fosfoinositida 3-quinasa p110? / ? clase IA modula la activación de los linfocitos T y la artritis inducida por colágenoarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Aragoneses-Fenoll, L.Montes-Casado, M.Ojeda, G.Acosta Ampudia, Yeny YasbleidyHerranz, J.Martínez, S.Blanco-Aparicio, C.Criado, G.Pastor, J.Dianzani, U.Portolés, P.Rojo, J.M.10336/26038oai:repository.urosario.edu.co:10336/260382022-05-02 07:37:13.54034https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
dc.title.TranslatedTitle.spa.fl_str_mv ETP-46321, un inhibidor dual de la fosfoinositida 3-quinasa p110? / ? clase IA modula la activación de los linfocitos T y la artritis inducida por colágeno
title ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
spellingShingle ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
T lymphocytes
CD28
ICOS
Phosphatidyl inositol-3 kinase
PI3K inhibitors
Rheumatoid arthritis
title_short ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
title_full ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
title_fullStr ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
title_full_unstemmed ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
title_sort ETP-46321, a dual p110?/? class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis
dc.subject.keyword.spa.fl_str_mv T lymphocytes
CD28
ICOS
Phosphatidyl inositol-3 kinase
PI3K inhibitors
Rheumatoid arthritis
topic T lymphocytes
CD28
ICOS
Phosphatidyl inositol-3 kinase
PI3K inhibitors
Rheumatoid arthritis
description Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110? and p110? class IA PI3K. Whereas the functioning of PI3K p110? in immune and autoimmune reactions is well established, the role of p110? is less well understood. Here, a novel dual p110?/? inhibitor (ETP-46321) and highly specific p110? (A66) or p110? (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4+ T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110? inhibitor than by the p110? inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-?), T-bet expression and NFAT activation. In activated CD4+ T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-? better than A66. The p110?/? inhibitor ETP-46321, or p110? plus p110? inhibitors also inhibited IL-21 secretion by differentiated CD4+ T follicular (Tfh) or IL-17-producing (Th17) helper cells. In vivo, therapeutic administration of ETP-46321 significantly inhibited responses to protein antigen as well as collagen-induced arthritis, as measured by antigen-specific antibody responses, secretion of IL-10, IL-17A or IFN-?, or clinical symptoms. Hence, p110? as well as p110? Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.
publishDate 2016
dc.date.created.spa.fl_str_mv 2016-04-15
dc.date.accessioned.none.fl_str_mv 2020-08-06T16:20:30Z
dc.date.available.none.fl_str_mv 2020-08-06T16:20:30Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.bcp.2016.02.005
dc.identifier.issn.none.fl_str_mv ISSN: 0006-2952
EISSN: 1873-2968
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/26038
url https://doi.org/10.1016/j.bcp.2016.02.005
https://repository.urosario.edu.co/handle/10336/26038
identifier_str_mv ISSN: 0006-2952
EISSN: 1873-2968
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 69
dc.relation.citationStartPage.none.fl_str_mv 56
dc.relation.citationTitle.none.fl_str_mv Biochemical Pharmacology
dc.relation.citationVolume.none.fl_str_mv Vol. 196
dc.relation.ispartof.spa.fl_str_mv Biochemical Pharmacology, ISSN: 0006-2952;EISSN: 1873-2968, Vol.196 (2016); pp.56-69
dc.relation.uri.spa.fl_str_mv https://www.sciencedirect.com/science/article/abs/pii/S0006295216000848?via%3Dihub
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.source.spa.fl_str_mv Biochemical Pharmacology
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167554643460096